Does the media prefer NAUT or TRNS?

In the previous week, Transcat had 1 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 4 mentions for Transcat and 3 mentions for Nautilus Biotechnology. Transcat's average media sentiment score of 1.14 beat Nautilus Biotechnology's score of 0.22 indicating that Transcat is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nautilus Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Transcat 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CTKB or NAUT?

In the previous week, Nautilus Biotechnology had 1 more articles in the media than Cytek Biosciences. MarketBeat recorded 3 mentions for Nautilus Biotechnology and 2 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 0.96 beat Nautilus Biotechnology's score of 0.22 indicating that Cytek Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytek Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nautilus Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to FEIM or NAUT?

In the previous week, Frequency Electronics had 3 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 6 mentions for Frequency Electronics and 3 mentions for Nautilus Biotechnology. Frequency Electronics' average media sentiment score of 0.76 beat Nautilus Biotechnology's score of 0.22 indicating that Frequency Electronics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Frequency Electronics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nautilus Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor NAUT or OPTX?

In the previous week, Syntec Optics had 2 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 5 mentions for Syntec Optics and 3 mentions for Nautilus Biotechnology. Syntec Optics' average media sentiment score of 0.92 beat Nautilus Biotechnology's score of 0.22 indicating that Syntec Optics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nautilus Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Syntec Optics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor NAUT or LAB?

In the previous week, Standard BioTools had 5 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 8 mentions for Standard BioTools and 3 mentions for Nautilus Biotechnology. Standard BioTools' average media sentiment score of 1.06 beat Nautilus Biotechnology's score of 0.22 indicating that Standard BioTools is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nautilus Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Standard BioTools 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Nautilus Biotechnology (NAUT) Competitors

$1.69 -0.08 (-4.52%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$1.62 -0.08 (-4.44%)

As of 07/24/2026 07:34 PM Eastern

Compare

NAUT vs. TRNS, CTKB, FEIM, OPTX, and LAB

Should you buy Nautilus Biotechnology stock or one of its competitors? MarketBeat compares Nautilus Biotechnology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nautilus Biotechnology include Transcat (TRNS), Cytek Biosciences (CTKB), Frequency Electronics (FEIM), Syntec Optics (OPTX), and Standard BioTools (LAB). These companies are all part of the "measuring and control equipment" industry.

How does Nautilus Biotechnology compare to Transcat?

Nautilus Biotechnology (NASDAQ:NAUT) and Transcat (NASDAQ:TRNS) are both small-cap measuring and control equipment companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk, media sentiment and analyst recommendations.

Nautilus Biotechnology has a beta of 0.8, indicating that its share price is 20% less volatile than the broader market. Comparatively, Transcat has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market.

Transcat has higher revenue and earnings than Nautilus Biotechnology. Nautilus Biotechnology is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.46	N/A
Transcat	$331.88M	2.39	$5.38M	$0.58	146.29

Transcat has a net margin of 1.62% compared to Nautilus Biotechnology's net margin of 0.00%. Transcat's return on equity of 5.84% beat Nautilus Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nautilus Biotechnology	N/A	-35.04%	-29.16%
Transcat	1.62%	5.84%	3.78%

50.7% of Nautilus Biotechnology shares are held by institutional investors. Comparatively, 98.3% of Transcat shares are held by institutional investors. 41.1% of Nautilus Biotechnology shares are held by insiders. Comparatively, 2.8% of Transcat shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Nautilus Biotechnology presently has a consensus price target of $4.00, suggesting a potential upside of 136.69%. Transcat has a consensus price target of $105.50, suggesting a potential upside of 24.34%. Given Nautilus Biotechnology's higher possible upside, equities research analysts plainly believe Nautilus Biotechnology is more favorable than Transcat.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Transcat	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Transcat had 1 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 4 mentions for Transcat and 3 mentions for Nautilus Biotechnology. Transcat's average media sentiment score of 1.14 beat Nautilus Biotechnology's score of 0.22 indicating that Transcat is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nautilus Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Transcat	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Transcat beats Nautilus Biotechnology on 12 of the 15 factors compared between the two stocks.

How does Nautilus Biotechnology compare to Cytek Biosciences?

Cytek Biosciences (NASDAQ:CTKB) and Nautilus Biotechnology (NASDAQ:NAUT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, media sentiment, profitability, risk, dividends, earnings and institutional ownership.

Nautilus Biotechnology has lower revenue, but higher earnings than Cytek Biosciences. Cytek Biosciences is trading at a lower price-to-earnings ratio than Nautilus Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytek Biosciences	$204.17M	2.82	-$66.54M	-$0.57	N/A
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.46	N/A

Cytek Biosciences has a beta of 1.17, suggesting that its stock price is 17% more volatile than the broader market. Comparatively, Nautilus Biotechnology has a beta of 0.8, suggesting that its stock price is 20% less volatile than the broader market.

69.5% of Cytek Biosciences shares are owned by institutional investors. Comparatively, 50.7% of Nautilus Biotechnology shares are owned by institutional investors. 10.4% of Cytek Biosciences shares are owned by company insiders. Comparatively, 41.1% of Nautilus Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Nautilus Biotechnology has a net margin of 0.00% compared to Cytek Biosciences' net margin of -36.25%. Cytek Biosciences' return on equity of -10.07% beat Nautilus Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytek Biosciences	-36.25%	-10.07%	-7.56%
Nautilus Biotechnology	N/A	-35.04%	-29.16%

Cytek Biosciences presently has a consensus price target of $5.69, indicating a potential upside of 27.52%. Nautilus Biotechnology has a consensus price target of $4.00, indicating a potential upside of 136.69%. Given Nautilus Biotechnology's higher probable upside, analysts plainly believe Nautilus Biotechnology is more favorable than Cytek Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Nautilus Biotechnology had 1 more articles in the media than Cytek Biosciences. MarketBeat recorded 3 mentions for Nautilus Biotechnology and 2 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 0.96 beat Nautilus Biotechnology's score of 0.22 indicating that Cytek Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytek Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nautilus Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Cytek Biosciences beats Nautilus Biotechnology on 8 of the 15 factors compared between the two stocks.

How does Nautilus Biotechnology compare to Frequency Electronics?

Frequency Electronics (NASDAQ:FEIM) and Nautilus Biotechnology (NASDAQ:NAUT) are both small-cap measuring and control equipment companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

Frequency Electronics has higher revenue and earnings than Nautilus Biotechnology. Frequency Electronics is trading at a lower price-to-earnings ratio than Nautilus Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Frequency Electronics	$63.23M	11.31	-$900K	-$0.09	N/A
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.46	N/A

Frequency Electronics has a beta of 0.71, indicating that its stock price is 29% less volatile than the broader market. Comparatively, Nautilus Biotechnology has a beta of 0.8, indicating that its stock price is 20% less volatile than the broader market.

Nautilus Biotechnology has a net margin of 0.00% compared to Frequency Electronics' net margin of -1.43%. Frequency Electronics' return on equity of -1.56% beat Nautilus Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Frequency Electronics	-1.43%	-1.56%	-0.98%
Nautilus Biotechnology	N/A	-35.04%	-29.16%

Frequency Electronics currently has a consensus target price of $43.67, suggesting a potential downside of 39.74%. Nautilus Biotechnology has a consensus target price of $4.00, suggesting a potential upside of 136.69%. Given Nautilus Biotechnology's higher possible upside, analysts clearly believe Nautilus Biotechnology is more favorable than Frequency Electronics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Frequency Electronics	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Frequency Electronics had 3 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 6 mentions for Frequency Electronics and 3 mentions for Nautilus Biotechnology. Frequency Electronics' average media sentiment score of 0.76 beat Nautilus Biotechnology's score of 0.22 indicating that Frequency Electronics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Frequency Electronics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nautilus Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

58.6% of Frequency Electronics shares are owned by institutional investors. Comparatively, 50.7% of Nautilus Biotechnology shares are owned by institutional investors. 28.0% of Frequency Electronics shares are owned by insiders. Comparatively, 41.1% of Nautilus Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Frequency Electronics beats Nautilus Biotechnology on 10 of the 15 factors compared between the two stocks.

How does Nautilus Biotechnology compare to Syntec Optics?

Nautilus Biotechnology (NASDAQ:NAUT) and Syntec Optics (NASDAQ:OPTX) are both small-cap measuring and control equipment companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk.

Nautilus Biotechnology presently has a consensus price target of $4.00, suggesting a potential upside of 136.69%. Given Nautilus Biotechnology's stronger consensus rating and higher probable upside, equities research analysts plainly believe Nautilus Biotechnology is more favorable than Syntec Optics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Syntec Optics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Syntec Optics has higher revenue and earnings than Nautilus Biotechnology. Syntec Optics is trading at a lower price-to-earnings ratio than Nautilus Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.46	N/A
Syntec Optics	$27.53M	10.32	-$1.79M	-$0.08	N/A

Nautilus Biotechnology has a beta of 0.8, meaning that its stock price is 20% less volatile than the broader market. Comparatively, Syntec Optics has a beta of -0.86, meaning that its stock price is 186% less volatile than the broader market.

50.7% of Nautilus Biotechnology shares are owned by institutional investors. 41.1% of Nautilus Biotechnology shares are owned by insiders. Comparatively, 0.8% of Syntec Optics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Syntec Optics had 2 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 5 mentions for Syntec Optics and 3 mentions for Nautilus Biotechnology. Syntec Optics' average media sentiment score of 0.92 beat Nautilus Biotechnology's score of 0.22 indicating that Syntec Optics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nautilus Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Syntec Optics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nautilus Biotechnology has a net margin of 0.00% compared to Syntec Optics' net margin of -10.95%. Syntec Optics' return on equity of -30.86% beat Nautilus Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nautilus Biotechnology	N/A	-35.04%	-29.16%
Syntec Optics	-10.95%	-30.86%	-12.35%

Summary

Nautilus Biotechnology beats Syntec Optics on 8 of the 15 factors compared between the two stocks.

How does Nautilus Biotechnology compare to Standard BioTools?

Nautilus Biotechnology (NASDAQ:NAUT) and Standard BioTools (NASDAQ:LAB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

50.7% of Nautilus Biotechnology shares are held by institutional investors. Comparatively, 53.7% of Standard BioTools shares are held by institutional investors. 41.1% of Nautilus Biotechnology shares are held by insiders. Comparatively, 26.8% of Standard BioTools shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Nautilus Biotechnology has higher earnings, but lower revenue than Standard BioTools. Nautilus Biotechnology is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.46	N/A
Standard BioTools	$86.26M	3.77	-$74.90M	$0.20	4.17

Nautilus Biotechnology presently has a consensus target price of $4.00, indicating a potential upside of 136.69%. Standard BioTools has a consensus target price of $1.35, indicating a potential upside of 62.03%. Given Nautilus Biotechnology's stronger consensus rating and higher probable upside, equities analysts plainly believe Nautilus Biotechnology is more favorable than Standard BioTools.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Standard BioTools has a net margin of 73.46% compared to Nautilus Biotechnology's net margin of 0.00%. Standard BioTools' return on equity of -8.18% beat Nautilus Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nautilus Biotechnology	N/A	-35.04%	-29.16%
Standard BioTools	73.46%	-8.18%	-6.43%

Nautilus Biotechnology has a beta of 0.8, indicating that its share price is 20% less volatile than the broader market. Comparatively, Standard BioTools has a beta of 1.42, indicating that its share price is 42% more volatile than the broader market.

In the previous week, Standard BioTools had 5 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 8 mentions for Standard BioTools and 3 mentions for Nautilus Biotechnology. Standard BioTools' average media sentiment score of 1.06 beat Nautilus Biotechnology's score of 0.22 indicating that Standard BioTools is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nautilus Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Standard BioTools	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Standard BioTools beats Nautilus Biotechnology on 10 of the 15 factors compared between the two stocks.

Get Nautilus Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NAUT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NAUT vs. The Competition

Export

Metric	Nautilus Biotechnology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$214.76M	$3.67B	$6.87B	$12.26B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-3.67	21.48	27.14	23.64
Price / Sales	N/A	170.08	517.06	88.99
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	1.36	7.88	10.28	6.07
Net Income	-$59M	$23.86M	$3.60B	$331.99M
7 Day Performance	-2.87%	-3.82%	-1.27%	-0.63%
1 Month Performance	-25.55%	-2.61%	-0.37%	-2.00%
1 Year Performance	122.98%	32.79%	18.30%	13.62%

Nautilus Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NAUT Nautilus Biotechnology	2.1514 of 5 stars	$1.69 -4.5%	$4.00 +136.7%	+122.1%	$214.76M	N/A	N/A	130	Upcoming Earnings Short Interest Increase
TRNS Transcat	3.9521 of 5 stars	$89.73 -2.8%	$105.50 +17.6%	+1.7%	$862.33M	$331.88M	154.71	1,413	Positive News
CTKB Cytek Biosciences	2.3786 of 5 stars	$4.62 +2.4%	$5.69 +23.1%	+33.9%	$582.43M	$201.49M	N/A	500	News Coverage
FEIM Frequency Electronics	1.158 of 5 stars	$58.93 +8.1%	$43.67 -25.9%	+171.4%	$536.39M	$69.81M	78.57	200
OPTX Syntec Optics	0.1749 of 5 stars	$8.20 -1.0%	N/A	+210.6%	$333.52M	$28.08M	N/A	3	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NAUT) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nautilus Biotechnology (NAUT) Competitors

NAUT vs. TRNS, CTKB, FEIM, OPTX, and LAB

How does Nautilus Biotechnology compare to Transcat?

Summary

How does Nautilus Biotechnology compare to Cytek Biosciences?

Summary

How does Nautilus Biotechnology compare to Frequency Electronics?

Summary

How does Nautilus Biotechnology compare to Syntec Optics?

Summary

How does Nautilus Biotechnology compare to Standard BioTools?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAUT vs. The Competition

Nautilus Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nautilus Biotechnology (NAUT) Competitors

NAUT vs. TRNS, CTKB, FEIM, OPTX, and LAB

How does Nautilus Biotechnology compare to Transcat?

Which has more risk & volatility, NAUT or TRNS?

Which has higher earnings & valuation, NAUT or TRNS?

Is NAUT or TRNS more profitable?

Do institutionals & insiders hold more shares of NAUT or TRNS?

Do analysts rate NAUT or TRNS?

Does the media prefer NAUT or TRNS?

Summary

How does Nautilus Biotechnology compare to Cytek Biosciences?

Which has stronger valuation & earnings, CTKB or NAUT?

Which has more risk and volatility, CTKB or NAUT?

Do institutionals and insiders have more ownership in CTKB or NAUT?

Is CTKB or NAUT more profitable?

Do analysts prefer CTKB or NAUT?

Does the media favor CTKB or NAUT?

Summary

How does Nautilus Biotechnology compare to Frequency Electronics?

Which has higher valuation and earnings, FEIM or NAUT?

Which has more risk and volatility, FEIM or NAUT?

Is FEIM or NAUT more profitable?

Do analysts recommend FEIM or NAUT?

Does the media refer more to FEIM or NAUT?

Do insiders and institutionals have more ownership in FEIM or NAUT?

Summary

How does Nautilus Biotechnology compare to Syntec Optics?

Do analysts prefer NAUT or OPTX?

Which has preferable valuation and earnings, NAUT or OPTX?

Which has more volatility and risk, NAUT or OPTX?

Do institutionals & insiders have more ownership in NAUT or OPTX?

Does the media favor NAUT or OPTX?

Is NAUT or OPTX more profitable?

Summary

How does Nautilus Biotechnology compare to Standard BioTools?

Do institutionals & insiders believe in NAUT or LAB?

Which has better valuation and earnings, NAUT or LAB?

Do analysts rate NAUT or LAB?

Is NAUT or LAB more profitable?

Which has more risk and volatility, NAUT or LAB?

Does the media favor NAUT or LAB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAUT vs. The Competition

Nautilus Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools